4basebio Plc Director/PDMR Shareholding

 
TIDM4BB 
 
11 May 2022 
 
                                 4basebio plc 
                                (the "Company") 
 
 
                              Director's Dealing 
 
4basebio PLC (AIM: 4BB), the specialist life sciences group focused on 
exploiting intellectual property in the field of cell and gene therapies and 
DNA vaccines, announces that, on 09 May 2022, Heikki Lanckriet, chief executive 
officer, acquired 500 ordinary shares at a price of 500 pence per share. 
 
As a result of the acquisition of ordinary shares, Heikki Lanckriet's 
beneficial holding, including shares held by persons closely associated with 
him, comprises 1,249,453 ordinary shares representing 10.14 per cent. of the 
Company's issued share capital. 
 
This announcement contains inside information for the purposes of Article 7 of 
EU Regulation 596/2014. 
 
For further enquiries, please contact: 
 
4basebio plc                                            [phone] 
 
Heikki Lanckriet, CEO 
 
Cairn Financial Advisers LLP (Nominated                 [phone] 
Adviser) 
 
Jo Turner / Sandy Jamieson 
 
finnCap Ltd (Broker)                                    [phone] 
 
Geoff Nash/Richard Chambers/Charlotte 
Sutcliffe 
 
 
Notification and public disclosure of transactions by persons discharging 
managerial responsibilities and persons closely associated with them 
 
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 
596/2014 
 
1.        Details of the person discharging managerial responsibilities/person 
closely associated 
 
a.        Name                                                    Heikki 
Lanckriet 
 
2.        Reason for notification 
 
a.        Position/Status                                   Chief Executive 
Officer 
 
b.        Initial notification/ Amendment    Initial 
 
3.        Details of the issuer, emission allowance market participant, auction 
platform, auctioneer or auction monitor 
 
a.        Name                                                    4basebio plc 
 
b.        LEI 
213800E2DX9EAIUNCB30 
 
4.        Details of the transaction(s): section to be repeated for (i) each 
type of instrument; (ii) each type of transaction; (iii) each date; and (iv) 
each place where transactions have been conducted 
 
a.        Description of the financial instrument, type Ordinary Shares of 
instrument 
 
Identification Code                            ISIN: GB00BMCLYF79 
 
 
b.        Nature of the transaction                Acquisition of ordinary 
shares 
 
 
c.         Price(s) and volume(s)       Volume(s)           Price (p) 
 
 
500 500p 
 
d.        Aggregated information 
 
- Aggregated Volume                        500 
- Price                                                    500 pence per share 
 
 
e.        Date of the transaction                    09/05/2022 
 
 
f.         Place of the transaction London Stock Exchange, AIM 
 
 
 
END 
 
 

(END) Dow Jones Newswires

May 11, 2022 06:57 ET (10:57 GMT)